Precision Biosciences IncDTIL
What Precision Biosciences Inc does.
We are a clinical stage gene editing company utilizing our novel proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. ARCUS differs from other technologies in the way it cuts, its smaller size, and its simpler structure. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus (“AAV”)). We believe that the ARCUS platform’s key capabilities and differentiating characteristics can be leveraged for effective and safe therapeutic outcomes.
DNA carries the genetic instructions for all basic functions of a living cell. These instructions are encoded in four different molecules, called bases, which are strung together in specific sequences to form genes. Each gene is responsible for a specific function in a cell, and the complete set of genes in a cell, which can consist of tens of thousands of genes and billions of individual bases, is known as a genome. The complete genome sequence has been determined for many organisms, including humans. This allows scientists to identify specific genes and determine how their unique sequences contribute to a particular cellular function. Studying variations in gene sequences further informs an understanding of why a cell behaves a certain way, which can greatly enhance understanding of what causes and how to treat aberrations that leads to disease.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $24.3M | $115.5M | $25.1M | $48.7M | $68.7M | $34.3M |
| Net income | -$109.0M | -$30.6M | -$111.6M | -$61.3M | $7.2M | -$45.7M |
| Free cash flow | -$92.4M | -$15.9M | -$49.1M | -$86.1M | -$58.7M | -$65.9M |
More on DTIL.
- Precision Biosciences Inc summary
- Precision Biosciences Inc financial statements
- Precision Biosciences Inc key metrics
- Precision Biosciences Inc health scores and style box
- Precision Biosciences Inc earnings
- Precision Biosciences Inc dividends
- Precision Biosciences Inc valuation
- Precision Biosciences Inc ownership and insiders
- Precision Biosciences Inc peers
Figures from Precision Biosciences Inc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.